Table 1 Clinical characteristics of the patients included in the discovery dataset.
From: A novel immune prognostic index for stratification of high-risk patients with early breast cancer
|  | Total | HR+/HER2− | HR+/HER2+ | HR−/HER2+ | TNBC |
|---|---|---|---|---|---|
(n = 916) | (n = 593) | (n = 93) | (n = 41) | (n = 189) | |
No. of patients (%) | No. of patients (%) | No. of patients (%) | No. of patients (%) | No. of patients (%) | |
Age (years) | |||||
≤ 50 | 312 (34.1) | 164 (27.7) | 41 (44.1) | 15 (36.6) | 92 (48.7) |
> 50 | 604 (65.9) | 429 (72.3) | 52 (55.9) | 26 (63.4) | 97 (51.3) |
Tumor size (cm) | |||||
≤ 2 | 507 (55.3) | 312 (52.6) | 46 (49.5) | 12 (29.3) | 137 (72.5) |
2–5 | 396 (43.2) | 272 (45.9) | 44 (47.3) | 29 (70.7) | 51 (27.0) |
> 5 | 13 (1.4) | 9 (1.5) | 3 (3.2) | 0 (0.0) | 1 (0.5) |
LN status | |||||
Negative | 735 (80.2) | 457 (77.1) | 74 (79.6) | 30 (73.2) | 174 (92.1) |
Positive | 181 (19.8) | 136 (22.9) | 19 (20.4) | 11 (26.8) | 15 (7.9) |
Histologic grade | |||||
1&2 | 650 (70.9) | 506 (85.3) | 67 (72.0) | 13 (31.7) | 64 (33.8) |
3 | 266 (29.0) | 87 (14.7) | 26 (28.0) | 28 (68.3) | 125 (66.1) |
